http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-11-13 10:00:182023-11-10 17:58:27Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s Disease
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-11-02 08:30:182023-11-01 15:08:21Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-10-10 11:49:132023-10-10 11:49:13Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-06-22 15:15:192023-06-23 11:34:21Mission Therapeutics founder to receive Knighthood in Birthday Honours List
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-03-06 11:33:182023-03-06 11:33:31Mission Therapeutics to Present at the Targeted Protein Degradation Europe Conference 2023
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-01-05 09:00:552023-01-05 08:39:52Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652
Scroll to top
